HPV-Related Disease Burden in Men and Women in the Czech Republic: A Claims Database Analysis
Author(s)
Vojtech Kamensky, Ing., PhD1, Jana Alahakoon, MSc.2, Jakub Zadak, MSc3, Karla Mothejlová, Ing1, Gleb Donin, MSc, PhD4, Juliana Grand Mullerova, MSc5, Martin Rožánek, doc. Ing., PhD6, Ales Tichopad, doc. Dr. rer. nat., Ph.D.6, Ivana Šarkanová, MSc, PhD6.
1Czech Technical University in Prague, Kladno, Czech Republic, 2MSD HH, Praha, Czech Republic, 3Merck Sharp & Dohme s.r.o., Prague, Czech Republic, 4Department of Biomedical Technology, Czech Technical University in Prague, Kladno, Czech Republic, 5Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic, Prague, Czech Republic, 6Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic, Prague, Czech Republic.
1Czech Technical University in Prague, Kladno, Czech Republic, 2MSD HH, Praha, Czech Republic, 3Merck Sharp & Dohme s.r.o., Prague, Czech Republic, 4Department of Biomedical Technology, Czech Technical University in Prague, Kladno, Czech Republic, 5Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic, Prague, Czech Republic, 6Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic, Prague, Czech Republic.
OBJECTIVES: It is well established that human papillomavirus (HPV) infection is a significant cause of infection-related cancer in both men and women. Economic studies of HPV-related cancers in Europe have primarily focused on cervical cancer and its precursor lesions. However, there has been a notable increase in the incidence of non-cervical HPV-related cancers in both sexes in recent years. This study aimed to assess the economic and epidemiological burden of HPV-associated diseases in men and women in the Czech Republic.
METHODS: A retrospective analysis was conducted utilising administrative claim data, collected over the period from 2017 to 2021 in the Czech Republic. The study identified individuals diagnosed with HPV-related diseases through the ICD-10 codes, and analysed their health-related costs, demographic details, and mortality data. The estimation of years of life lost (YLL) and indirect costs associated with premature death was based on gender-specific life expectancy and average salaries employing the human capital approach.
RESULTS: The study identified over 110,000 incident cases of HPV-related diseases, with the majority of these being females (84.2%). The mean age of patients was 39.7 years, with males exhibiting a slightly younger age (39 years) than females (39.9 years). The total medical cost of HPV-related diseases over the monitored period exceeded 1 billion CZK. It was estimated that 27,436 years of potential life were lost due to premature mortality. The indirect costs, defined as lost salary, were calculated to exceed 2.92 billion CZK.
CONCLUSIONS: This retrospective analysis provided a comprehensive overview of the economic and epidemiological burden of HPV-related diseases in the Czech Republic. The findings highlighted the significant financial burden on healthcare resources, particularly in the context of cancer treatments. This underscores the necessity for informed policy decisions and cost-effectiveness analyses in the context of HPV interventions, including vaccination and preventive programmes.
METHODS: A retrospective analysis was conducted utilising administrative claim data, collected over the period from 2017 to 2021 in the Czech Republic. The study identified individuals diagnosed with HPV-related diseases through the ICD-10 codes, and analysed their health-related costs, demographic details, and mortality data. The estimation of years of life lost (YLL) and indirect costs associated with premature death was based on gender-specific life expectancy and average salaries employing the human capital approach.
RESULTS: The study identified over 110,000 incident cases of HPV-related diseases, with the majority of these being females (84.2%). The mean age of patients was 39.7 years, with males exhibiting a slightly younger age (39 years) than females (39.9 years). The total medical cost of HPV-related diseases over the monitored period exceeded 1 billion CZK. It was estimated that 27,436 years of potential life were lost due to premature mortality. The indirect costs, defined as lost salary, were calculated to exceed 2.92 billion CZK.
CONCLUSIONS: This retrospective analysis provided a comprehensive overview of the economic and epidemiological burden of HPV-related diseases in the Czech Republic. The findings highlighted the significant financial burden on healthcare resources, particularly in the context of cancer treatments. This underscores the necessity for informed policy decisions and cost-effectiveness analyses in the context of HPV interventions, including vaccination and preventive programmes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE522
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Reproductive & Sexual Health